Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial-Reference-Cited by-同舟云学术

Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial

Published:2014-12 Issue:13 Volume:15 Page:1442-1450
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Fizazi Karim,Pagliaro Lance,Laplanche Agnes,Fléchon Aude,Mardiak Josef,Geoffrois Lionnel,Kerbrat Pierre,Chevreau Christine,Delva Remy,Rolland Frederic,Theodore Christine,Roubaud Guilhem,Gravis Gwenaëlle,Eymard Jean-Christophe,Malhaire Jean-Pierre,Linassier Claude,Habibian Muriel,Martin Anne-Laure,Journeau Florence,Reckova Maria,Logothetis Christopher,Culine Stephane

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer;Beyer;Ann Oncol,2013

2. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy;J Clin Oncol,2010

3. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide;Williams;N Engl J Med,1987

4. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors;Ozols;J Clin Oncol,1988

5. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol;Nichols;J Clin Oncol,1991

Cited by 169 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial;Journal of Clinical Oncology;2024-08-21

2. MicroRNA for Prediction of Teratoma and Viable Germ Cell Tumor after Chemotherapy;Urologic Clinics of North America;2024-08

3. Regionalization of Testis Cancer Care—Is It Necessary?;Urologic Clinics of North America;2024-08

4. Half-life of serum alpha-fetoprotein in prepubertal testicular yolk sac tumors: an index significantly associated with prognosis;World Journal of Urology;2024-07-22

5. SEOM-GG clinical guidelines for the management of germ-cell testicular cancer (2023);Clinical and Translational Oncology;2024-07-03